Figure 2. Viperin differently induces ISG expression in BMDMs and MEFs treated with type II IFN. (A-D) The effect of viperin on expression of ISGs in BMDMs and MEFs upon type II IFN treatment. WT and viperin KO BMDMs (A, B) or MEFs (C, D) were treated with or without IFN-γ (100 ng/ml) for 24 h. The mRNA expression levels of ISGs in the cells were measured by qRT-PCR and normalized to β-actin mRNA (A, C). Data are presented as mean±SEM of triplicate samples and are representative of three individual experiments. Expression of viperin and ISG15 proteins in the cells was detected by immunoblot using anti-viperin (MaP.VIP) or anti-ISG15 antibody (B, D). GRP94 served as a protein-loading control. Quantitation of ISG15 protein level was normalized to GRP94.

^*p<0.05; ^**p<0.01; ^***p<0.001.